Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Our CompaniesNewsroomInsights

About PPF Group

About UsPeople and statutory bodiesFinancial results & statementsReports and documents

Social responsibility

Social responsibilitySustainability
For MediaContactsCareers
cs

News to Email

Get the latest press releases, interviews, podcasts, and insights. 

Subscribe To News

Follow us

For Media

  • Press Releases
  • Interviews and Podcasts
  • Subscribe To News
  • Downloads
  • Contacts

MAY BE OF INTEREST

  • Our Companies
  • Newsroom
  • Insights

Contacts

  • PPF Group Companies
  • Terms of use
  • Data protection
  • Sitemap
  • Cookies policy

2026 © PPF Group

Most often you are looking for

Annual ReportsInsightsVisions and StrategiesPress Releases

  • Insights

  • Biotech Market / Business Intelligence

Sotio Biotech

7/8/2024

July 2024 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

by Jakub Jarolím, Business Intelligence Department

Share on social networks

Share on social networks

Print

Copy link

Market

Fed holds interest rates steady, but a cut is expected in coming months; NBI added 7 %

Buysiders and bankers are optimistic headed into 3Q24, as markets are rewarding positive catalysts. But uncertainty over the Fed’s timing on interest rate cuts is keeping a lid on how far the optimism can extend. Fed maintained rates steady, a cut is expected in coming months and NBI added 7 %.

News detail

Antibody-Drug Conjugates

Padcev plus Keytruda received positive CHMP opinion for first-line bladder cancer tretment

Astellas announced that EMA’s CHMP has adopted a positive opinion recommending approval of Padcev in combination with Keytruda for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy. 

News detail

Interleukin-15 and Interleukin-2

Innovent presented Phase 1 data of its PD-1/IL-2α-bias bispecific antibody fusion protein

Egle Therapeutics, a biotech company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto- immunity, will deliver an oral presentation at The Promise of Interleukin-2 Therapy meeting taking place in Paris. 

News detail

Cell Therapies

Carvykti achieved statistically significant improvement in OS in CARTITUDE-4

Johnson & Johnson announced positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating Carvykti (cilta-cel) compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) for the treatment of patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy.

News detail

Other Innovative Treatment Areas

Astellas received positive CHMP opinion for zolbetuximab plus chemo in gastric cancer

Astellas announced that the EMA’s CHMP adopted a positive opinion recommending the approval of zolbetuximab in the EU.

News detail

DISCLAIMER / SOTIO

Legal Notice (duplicate) (duplicate) (duplicate) (duplicate)

News detail